Axiom Investors LLC DE Has $335.17 Million Holdings in Boston Scientific Co. (NYSE:BSX)

Axiom Investors LLC DE raised its stake in shares of Boston Scientific Co. (NYSE:BSX) by 208.2% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 3,752,430 shares of the medical equipment provider’s stock after purchasing an additional 2,535,007 shares during the period. Boston Scientific accounts for 2.5% of Axiom Investors LLC DE’s portfolio, making the stock its 11th largest holding. Axiom Investors LLC DE’s holdings in Boston Scientific were worth $335,167,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors also recently added to or reduced their stakes in the business. D.A. Davidson & CO. raised its holdings in Boston Scientific by 3.2% during the 3rd quarter. D.A. Davidson & CO. now owns 10,945 shares of the medical equipment provider’s stock worth $917,000 after purchasing an additional 342 shares during the last quarter. Townsquare Capital LLC lifted its position in shares of Boston Scientific by 191.9% in the third quarter. Townsquare Capital LLC now owns 26,896 shares of the medical equipment provider’s stock valued at $2,254,000 after buying an additional 17,683 shares during the last quarter. Glenmede Trust Co. NA boosted its holdings in shares of Boston Scientific by 19.0% during the third quarter. Glenmede Trust Co. NA now owns 20,463 shares of the medical equipment provider’s stock worth $1,715,000 after acquiring an additional 3,261 shares during the period. CreativeOne Wealth LLC boosted its holdings in Boston Scientific by 62.0% in the 3rd quarter. CreativeOne Wealth LLC now owns 4,478 shares of the medical equipment provider’s stock valued at $375,000 after purchasing an additional 1,714 shares during the period. Finally, Hantz Financial Services Inc. increased its position in shares of Boston Scientific by 0.8% in the third quarter. Hantz Financial Services Inc. now owns 33,367 shares of the medical equipment provider’s stock worth $2,796,000 after purchasing an additional 263 shares during the period. 89.07% of the stock is owned by institutional investors.

Analysts Set New Price Targets

A number of analysts have recently commented on BSX shares. Needham & Company LLC reissued a “hold” rating on shares of Boston Scientific in a research note on Monday, March 3rd. Deutsche Bank Aktiengesellschaft raised Boston Scientific from a “hold” rating to a “buy” rating and set a $108.00 price objective for the company in a report on Friday, January 10th. Argus set a $130.00 price target on shares of Boston Scientific in a report on Tuesday, February 18th. Stifel Nicolaus increased their target price on shares of Boston Scientific from $100.00 to $115.00 and gave the company a “buy” rating in a research report on Thursday, February 6th. Finally, Wells Fargo & Company boosted their target price on shares of Boston Scientific from $100.00 to $118.00 and gave the company an “overweight” rating in a report on Thursday, February 6th. Two equities research analysts have rated the stock with a hold rating, twenty-one have given a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $108.91.

Insider Activity at Boston Scientific

In other news, EVP John Bradley Sorenson sold 1,201 shares of the company’s stock in a transaction on Friday, February 14th. The stock was sold at an average price of $106.31, for a total transaction of $127,678.31. Following the sale, the executive vice president now owns 25,443 shares of the company’s stock, valued at approximately $2,704,845.33. This represents a 4.51 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP Jeffrey B. Mirviss sold 4,675 shares of the stock in a transaction on Monday, February 24th. The shares were sold at an average price of $104.25, for a total value of $487,368.75. Following the completion of the transaction, the executive vice president now directly owns 28,454 shares in the company, valued at $2,966,329.50. This trade represents a 14.11 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders sold 137,302 shares of company stock valued at $14,319,269. 0.50% of the stock is owned by company insiders.

Boston Scientific Stock Down 1.5 %

BSX stock opened at $99.29 on Monday. Boston Scientific Co. has a 12 month low of $66.80 and a 12 month high of $107.17. The company has a debt-to-equity ratio of 0.41, a current ratio of 1.08 and a quick ratio of 1.02. The company has a market capitalization of $146.86 billion, a P/E ratio of 79.43, a price-to-earnings-growth ratio of 2.79 and a beta of 0.77. The firm’s fifty day simple moving average is $102.16 and its 200-day simple moving average is $93.18.

Boston Scientific (NYSE:BSX) last announced its earnings results on Wednesday, February 5th. The medical equipment provider reported $0.70 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.65 by $0.05. Boston Scientific had a return on equity of 17.80% and a net margin of 11.07%. As a group, equities research analysts forecast that Boston Scientific Co. will post 2.85 earnings per share for the current year.

About Boston Scientific

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.